For example, cabozantinib is a multi-kinase inhibitor of VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET and TIE -2, and regorafenib exhibits a broad spectrum of activity with inhibition of tyrosine kinases involved in tumor angiogenesis mechanisms (e.g., PDGFR, FGFRs 1–2, VEGFRs 1–3, TIE2), proliferation (RET, RAF, KIT), tumor microenvironment and metastasis processes (VEGFR2–3, PDGFR). Here, NTRK2 is linked to neoplasm.